Betahistine dihydrochloride is under clinical development by Altamira Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Betahistine dihydrochloride’s likelihood of approval (LoA) and phase transition for Vertigo took place on 08 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Betahistine dihydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Betahistine dihydrochloride overview
Betahistine dihydrochloride is under development for the treatment of vestibular vertigo, epilepsy and obesity-associated Prader Willi syndrome. The drug candidate is a a formulation of betahistine, which is administered as a nasal spray. It targets histamine H1 and H3 receptors. It was also under development for the treatment of Meniere's disease, otitis media with effusion (OME or glue ear) and eustachian tube dysfunction.
Altamira Therapeutics overview
Altamira Therapeutics formerly Auris Medical Holding Ltd, is a clinical-stage biopharmaceutical company with a focus on neurotology and CNS disorders. The company’s pipeline product candidates are in various clinical phases intended for the treatment of acute inner ear tinnitus, post-acute inner ear tinnitus, tinnitus, Vertigo, sudden loss of hearing, antipsychotic-induced weight gain, somnolence, airborne allergens and viruses. It has research collaboration and licensing agreements with Biotechnology companies including Xigen and Inserm. Auris Medical is headquartered in Hamilton, Bermuda.
Quick View Betahistine dihydrochloride LOA Data
|Highest Development Stage|